5JD Stock Overview
Through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ExpreS2ion Biotech Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.093 |
| 52 Week High | kr0.47 |
| 52 Week Low | kr0.038 |
| Beta | 1.75 |
| 1 Month Change | -50.53% |
| 3 Month Change | -64.50% |
| 1 Year Change | -74.02% |
| 3 Year Change | -97.70% |
| 5 Year Change | n/a |
| Change since IPO | -95.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5JD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.3% | 0.5% | -0.3% |
| 1Y | -74.0% | -25.8% | 4.5% |
Return vs Industry: 5JD underperformed the German Biotechs industry which returned -25.8% over the past year.
Return vs Market: 5JD underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| 5JD volatility | |
|---|---|
| 5JD Average Weekly Movement | 27.8% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5JD's share price has been volatile over the past 3 months.
Volatility Over Time: 5JD's weekly volatility has decreased from 52% to 28% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 20 | Bent Frandsen | www.expres2ionbio.com |
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase III clinical trial. It also develops influenza, breast cancer, and malaria vaccines.
ExpreS2ion Biotech Holding AB (publ) Fundamentals Summary
| 5JD fundamental statistics | |
|---|---|
| Market cap | €5.80m |
| Earnings (TTM) | -€7.11m |
| Revenue (TTM) | €669.31k |
8.7x
P/S Ratio-0.8x
P/E RatioIs 5JD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5JD income statement (TTM) | |
|---|---|
| Revenue | kr7.77m |
| Cost of Revenue | kr3.32m |
| Gross Profit | kr4.44m |
| Other Expenses | kr86.98m |
| Earnings | -kr82.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 57.22% |
| Net Profit Margin | -1,062.62% |
| Debt/Equity Ratio | 0.6% |
How did 5JD perform over the long term?
See historical performance and comparison